Search research articles
Contact Us
Filters
Showing results (141-150 of 153) with videos related to
Page
of 16
Sort By:
Blood Advances
|
February 5, 2026
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter's transformation
Katharine Louise Lewis, Sarit E Assouline, Ross Ian Baker, et al.
Blood
|
December 4, 2023
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas
Stephen J Schuster, Ling-Yuh Huw, Christopher R Bolen, et al.
The Lancet. Oncology
|
July 8, 2022
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
Lihua E Budde, Laurie H Sehn, Matthew Matasar, et al.
Nature Communications
|
January 2, 2025
Gestational diabetes mellitus causes genome hyper-methylation of oocyte via increased EZH2
Hong-Yan Guo, Shou-Bin Tang, Li-Jun Li, et al.
Blood Advances
|
November 21, 2024
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas
Elise A Chong, Elicia Penuel, Ellen B Napier, et al.
Blood
|
October 24, 2024
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies
Laurie H Sehn, Nancy L Bartlett, Matthew J Matasar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 28, 2024
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study
Lihua E Budde, Sarit Assouline, Laurie H Sehn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2021
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
Lihua E Budde, Sarit Assouline, Laurie H Sehn, et al.
Blood Advances
|
April 17, 2023
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma
Nancy L Bartlett, Sarit Assouline, Pratyush Giri, et al.
Nature Biomedical Engineering
|
April 19, 2022
Reduction of mtDNA heteroplasmy in mitochondrial replacement therapy by inducing forced mitophagy
Xiao-Yan Fan, Lei Guo, Lei-Ning Chen, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 153) with videos related to
Sort By:
Page
of 16
Blood Advances
|
February 5, 2026
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter's transformation
Katharine Louise Lewis, Sarit E Assouline, Ross Ian Baker, et al.
Blood
|
December 4, 2023
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas
Stephen J Schuster, Ling-Yuh Huw, Christopher R Bolen, et al.
The Lancet. Oncology
|
July 8, 2022
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
Lihua E Budde, Laurie H Sehn, Matthew Matasar, et al.
Nature Communications
|
January 2, 2025
Gestational diabetes mellitus causes genome hyper-methylation of oocyte via increased EZH2
Hong-Yan Guo, Shou-Bin Tang, Li-Jun Li, et al.
Blood Advances
|
November 21, 2024
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas
Elise A Chong, Elicia Penuel, Ellen B Napier, et al.
Blood
|
October 24, 2024
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies
Laurie H Sehn, Nancy L Bartlett, Matthew J Matasar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 28, 2024
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study
Lihua E Budde, Sarit Assouline, Laurie H Sehn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2021
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
Lihua E Budde, Sarit Assouline, Laurie H Sehn, et al.
Blood Advances
|
April 17, 2023
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma
Nancy L Bartlett, Sarit Assouline, Pratyush Giri, et al.
Nature Biomedical Engineering
|
April 19, 2022
Reduction of mtDNA heteroplasmy in mitochondrial replacement therapy by inducing forced mitophagy
Xiao-Yan Fan, Lei Guo, Lei-Ning Chen, et al.
Page
of 16